Transcriptome analysis of the compound 2a-treated cancer cells suggested that the downregulation of protein tyrosine phosphatase receptor type K (PTPRK) serves as a biomarker for monitoring anti-tumor effects of RM [13]. This evidence concerns the gene PTPRK and neoplasm.